Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TELAT-40 H
- Development stage
- Phase 4
- Lead developer
- Apostle Remedies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TELAT-40 H is a fixed-dose combination tablet developed by Apostle Remedies for the treatment of hypertension. It contains telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan works by selectively blocking the binding of angiotensin II to the type-1 angiotensin II receptor (AGTR1), leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits the solute carrier family 12 member 3 (SLC12A3) sodium-chloride cotransporter in the renal distal convoluted tubules, promoting the excretion of sodium and water to reduce blood volume. Together, these complementary mechanisms provide synergistic blood pressure reduction in patients whose hypertension is not adequately controlled by monotherapy.
- Brand names
- Actelsar HCTEritel HKITEL-HMicardis HCTMicardis PlusNumistel-HPritorPlusSARtel HTAZloC-HTELAT-40 HTELAT40 HTELAT 40 HTelista-HTelma HTelmikind-HTelmineo HTELsartan-HTelsar HTelvas HTemsan-H
- Other names
- telmisartan + hydrochlorothiazidetelmisartan and hydrochlorothiazidetelmisartan/HCTZtelmisartan/hydrochlorothiazide
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)
Beyond the preview
Go deeper on TELAT-40 H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TELAT-40 H.